LFA President & CEO Sandra C. Raymond Comments on First Potential Lupus Treatment in 50 Years

Today, Human Genome Sciences (HGS) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus. When the 52-week study concluded, the lupus patients who were treated with BENLYSTA had improvement in overall disease activity without clinically significant flare-ups in one or more isolated organs when compared to patients who received the placebo.

To mark this historic day, Sandra C. Raymond, President and Chief Executive Officer of the Lupus Foundation of America (LFA), has issued the following videotaped statement, which celebrates this milestone. Click on the image below to watch her video.